I don't remember the company name but there is research and possibly clinical trials underway for eosiniphilic BE.

Boehringer-Ingelheim is also working on a neutrophilic type drug for bronchiectasis with a better safety profile than brensocatib. According to website they are in clinical trials stage 2. It's estimated that there are 500,000 people in the USA alone who suffer with NCBE.
https://www.boehringer-ingelheim.com/human-health/lung-diseases/phase-ii-trials-patients-bronchiectasis

https://pmc.ncbi.nlm.nih.gov/articles/PMC11770772/
WILLOW-trial , n=256
the annualised exacerbation rate was lower for patients treated with brensocatib
regardless of blood eosinophil counts